Columvi (Glofitamab)
Glofitamab 10 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 15249N
AUTHORITY_REQUIREDWhat it costs
AU$5266.1 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-03-01.
- • Repeats: 10.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Continuing treatment (Cycles 2-12)
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
The treatment must be given in combination with gemcitabine and oxaliplatin for the first 8 cycles unless the patient has a contraindication/toxicity necessitating discontinuation of one or both chemotherapy components; AND
Patient must not have developed disease progression while being treated with this drug for this condition; AND
The treatment must not exceed a total of 12 cycles of this drug for this indication, regardless of whether treatment was non-PBS or PBS-subsidised.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Transitioning from non-PBS to PBS-subsidised treatment - Grandfather arrangements
Patient must have received non-PBS-subsidised treatment with this drug for this PBS condition prior to 1 March 2026; AND
Patient must have been unable to receive treatment with CAR-T cell therapy prior to commencing treatment with this drug for this condition; AND
Patient must have been unsuitable for stem cell transplant prior to commencing treatment with this drug for this condition; AND
Patient must have had a WHO performance status of 2 or less prior to commencing treatment with this drug for this condition; AND
Patient must not have developed disease progression while being treated with this drug for this condition; AND
The treatment must be given in combination with gemcitabine and oxaliplatin for the first 8 cycles unless the patient has a contraindication/toxicity necessitating discontinuation of one or both chemotherapy components; AND
The treatment must not exceed a total of 12 cycles of this drug for this indication, regardless of whether treatment was non-PBS or PBS-subsidised.
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.